Advertisement

Advances in Therapy

, Volume 28, Issue 11, pp 986–999 | Cite as

Idiopathic pulmonary fibrosis: Treatment update

  • Oisin J. O’Connell
  • Marcus P. Kennedy
  • Michael T. Henry
Review

Abstract

Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial pneumonias. Despite multiple recent clinical trials, there is no strong evidence supporting a survival advantage for any agent in the management of patients with IPF. The limited effectiveness of current treatment regimes has led to a search for novel therapies including antifibrotic strategies. This article reviews the evidence supporting the treatments currently used in the management of IPF.

Keywords

antifibrotic idiopathic pulmonary fibrosis patient management treatment 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.PubMedCrossRefGoogle Scholar
  2. 2.
    American Thoracic Society. Classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2002;65:277–304.Google Scholar
  3. 3.
    American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. Am J Respir Crit Care Med. 2000;161:646–664.Google Scholar
  4. 4.
    Navaratnam V, Fleming KM, West J, et al. The rising incidence of idiopathic pulmonary fibrosis in the UK. Thorax. 2011;66:462–467.PubMedCrossRefGoogle Scholar
  5. 5.
    Flaherty KR, Travis WD, Colby TV, et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med. 2001;164:1722–1727.PubMedGoogle Scholar
  6. 6.
    Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med. 2003;168:531–537.PubMedCrossRefGoogle Scholar
  7. 7.
    Hansell DM, Bankier AA, Macmahon H, McLoud TC, Muller NL, Remy J. Fleischner Society glossary of terms for thoracic imaging. Radiology. 2008;246:697–722.PubMedCrossRefGoogle Scholar
  8. 8.
    Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176:636–643.PubMedCrossRefGoogle Scholar
  9. 9.
    King TE Jr, Safrin S, Starko KM, et al. Analyses of efficacy end points in a controlled trial of interferon gamma-1b for idiopathic pulmonary fibrosis. Chest. 2005;127:171–177PubMedCrossRefGoogle Scholar
  10. 10.
    Raghu G, Brown KK, Bradford WZ, et al. A placebocontrolled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2004;350:125–133.PubMedCrossRefGoogle Scholar
  11. 11.
    Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005;353:2229–2242.PubMedCrossRefGoogle Scholar
  12. 12.
    King TE Jr, Behr J, Brown KK, et al. BUILD-1: a randomized placebo controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;177:75–81.PubMedCrossRefGoogle Scholar
  13. 13.
    Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo controlled trial. Am J Respir Crit Care Med. 2008;178:948–955.PubMedCrossRefGoogle Scholar
  14. 14.
    King, T. E. Jr, Albera C, Bradford WZ, et al.; INSPIRE Study Group. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo controlled trial. Lancet. 2009;374:222–228.PubMedCrossRefGoogle Scholar
  15. 15.
    Bouros D. Pirfenidone for idiopathic pulmonary fibrosis. Lancet. 2011;377:1727–1729.PubMedCrossRefGoogle Scholar
  16. 16.
    Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35:821–829PubMedCrossRefGoogle Scholar
  17. 17.
    The Idiopathic Pulmonary Fibrosis Clinical Research Network. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med. 2010;363: 620–628.CrossRefGoogle Scholar
  18. 18.
    Daniels CE, Lasky JA, Limper AH, et al. Imatinib treatment for idiopathic pulmonary fibrosis. Randomized placebo-controlled trial results. Am J Respir Crit Care Med. 2010;181:604–610.PubMedCrossRefGoogle Scholar
  19. 19.
    Lama VN, Flaherty KR, Toews GB, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003;168:1084–1090.PubMedCrossRefGoogle Scholar
  20. 20.
    Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med. 1998;157:1301–1315.PubMedGoogle Scholar
  21. 21.
    Chambers RC. Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention? Br J Pharmacol. 2008;153:S367–S378.PubMedCrossRefGoogle Scholar
  22. 22.
    Selman M, Pardo A. Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proc Am Thorac Soc. 2006;3:364–372.PubMedCrossRefGoogle Scholar
  23. 23.
    Richeldi L, Davies HR, Ferrara G, Franco F. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev. 2003;(3):CD002880.Google Scholar
  24. 24.
    Bradley B, Branley HM, Egan JJ, et al.; British Thoracic Society Interstitial Lung Disease Guideline Group, British Thoracic Society Standards of Care Committee Thoracic Society of Australia New Zealand Thoracic Society Irish Thoracic Society. Interstitial lung disease guidelines. The British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax. 2008;63(suppl. 5):v1–v58PubMedGoogle Scholar
  25. 25.
    Raghu G, Depaso WJ, Cain K, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am rev Respir Dis. 1991;144:291–296.PubMedCrossRefGoogle Scholar
  26. 26.
    Davies HR, Richeldi L, Walters EH. Immunomodulatory agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev. 2003;(3):CD003134.Google Scholar
  27. 27.
    Collard HR, Ryu JH, Douglas WW, et al. Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis. Chest. 2004;125:2169–2174.PubMedCrossRefGoogle Scholar
  28. 28.
    Payne K, Newman W, Fargher E et al. TPMT testing in rheumatology: any better than routine monitoring? Rheumatology. 2007;46:727–729.PubMedCrossRefGoogle Scholar
  29. 29.
    Hunninghake GW. Antioxidant therapy for idiopathic pulmonary fibrosis. N Engl J Med. 2005;353:2285–2287.PubMedCrossRefGoogle Scholar
  30. 30.
    Nicod LP. Pirfenidone in IPF. Lancet. 1999;354:268–269.PubMedCrossRefGoogle Scholar
  31. 31.
    Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171:1040–1047.PubMedCrossRefGoogle Scholar
  32. 32.
    Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomized trials. Lancet. 2011;377:1760–1769.PubMedCrossRefGoogle Scholar
  33. 33.
    Spagnolo P, Del Giovane C, Luppi F, et al. Nonsteroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev. 2010(8;9):CD003134.Google Scholar
  34. 34.
    Ziesche R., Hofbauer E., Wittmann K., Petkov V, Block LH. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 1999;341:1264–1269.PubMedCrossRefGoogle Scholar
  35. 35.
    Daniels CE, Wilkes MC, Edens M, et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest. 2004;114:1308–1316PubMedGoogle Scholar
  36. 36.
    Lettieri CJ, Nathan SD, Barnett SD, et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2006;129:746–752.PubMedCrossRefGoogle Scholar
  37. 37.
    Corte, TJ, Wort SJ, Wells AU. Pulmonary hypertension in idiopathic pulmonary fibrosis: a review. Sarcoidosis Vasc Diffuse Lung Dis. 2009;26:7–19.PubMedGoogle Scholar
  38. 38.
    Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet. 2002;360:895–900.PubMedCrossRefGoogle Scholar
  39. 39.
    Mubarak K. Sildenafil in idiopathic pulmonary fibrosis. N Engl J Med. 2010;363:2170PubMedGoogle Scholar
  40. 40.
    Maher TM. Sildenafil in idiopathic pulmonary fibrosis. N Engl J Med. 2010;363:2169PubMedCrossRefGoogle Scholar
  41. 41.
    Imokawa S, Sato A, Hayakawa H, Kotani M, Urano T, Takada A. Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic pulmonary fibrosis and systemic sclerosis. Am J Respir Crit Care Med. 1997;156:631–636.PubMedGoogle Scholar
  42. 42.
    Kubo H, Nakayama K, Yanai M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest. 2005;128:1475–1482.PubMedCrossRefGoogle Scholar
  43. 43.
    Raghu G, Freudenberger TD, Yang S, et al. High prevalence of abnormal gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J. 2006;27:136–142.PubMedCrossRefGoogle Scholar
  44. 44.
    Raghu G, Yang ST, Spada C, Hayes J, Pellegrini CA. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis. Chest. 2006;129:794–800.PubMedCrossRefGoogle Scholar
  45. 45.
    Han MK. High prevalence of abnormal acid gastrooesophageal reflux in idiopathic pulmonary fibrosis. Eur Resp J. 2006;28:884–885.CrossRefGoogle Scholar
  46. 46.
    Hubbard RB, Smith C, Jeune I. The association between idiopathic pulmonary fibrosis and vascular disease. Am J Respir Crit Care Med. 2008;178:1257–1261.PubMedCrossRefGoogle Scholar
  47. 47.
    Alfredo NC, Santana RA, Kairalla CR, et al. Potential role of statin use in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;177:1048.Google Scholar
  48. 48.
    Watts KL, Sampson EM, Schultz GS, Spiteri MA. Simvastatin inhibits growth factor expression and modulates profibrogenic markers in lung fibroblasts. Am J Respir Cell Mol Biol. 2005;32:290–300.PubMedCrossRefGoogle Scholar
  49. 49.
    Nadrous HF, Ryu JH, Douglas WW, Decker PA, Olson EJ. Impact of angiotensin-converting enzyme inhibitors and statins on survival in idiopathic pulmonary fibrosis. Chest. 2004;126:438–446.PubMedCrossRefGoogle Scholar
  50. 50.
    Naji NA, Connor MC, Donnelly SC, McDonnell TJ. Effectiveness of pulmonary rehabilitation in restrictive lung disease. J Cardiopulm Rehab. 2006;26:237–243.CrossRefGoogle Scholar
  51. 51.
    Nishiyama O, Kondoh Y, Kimura T, et al. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology. 2008;13:394–399.PubMedCrossRefGoogle Scholar
  52. 52.
    Holland AE, Hill CJ, Conron M, Munro P, McDonald CF. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax. 2008;63:549–554.PubMedCrossRefGoogle Scholar
  53. 53.
    Mogulkoc N, Brutsche MH, Bishop PW, Greaves SM, Horrocks AW, Egan JJ. Pulmonary function in Idiopathic pulmonary fibrosis and referral for lung transplantation. Am J Respir Crit Care Med. 2001;164:103–108.PubMedGoogle Scholar
  54. 54.
    Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update. J Heart Lung Transplant. 2006;25:745–55.PubMedCrossRefGoogle Scholar
  55. 55.
    Whelan P, Dunitz JM, Kelly RF, et al. Effect of preoperative pulmonary artery pressure on early survival after lung transplantation for idiopathic pulmonary fibrosis. J Heart Lung Transplant. 2005;24:1269–1274.PubMedCrossRefGoogle Scholar
  56. 56.
    Souza CA, Müller NL, Flint J, et al. Idiopathic pulmonary fibrosis: spectrum of high-resolution CT findings. AJR Am J Roentgenol. 2005;185:1531–1539.PubMedCrossRefGoogle Scholar
  57. 57.
    Ma Y, Seneviratne CK, Koss M. Idiopathic pulmonary fibrosis and malignancy. Curr Opin Pulm Med. 2001;7:278–282.PubMedCrossRefGoogle Scholar
  58. 58.
    Jeon TY, Lee KS, Yi CA, et al. Incremental value of PET/CT over CT for mediastinal nodal staging of non-small cell lung cancer: comparison between patients with and without idiopathic pulmonary fibrosis. AJR Am J Roentgenol. 2010;195:370–376.PubMedCrossRefGoogle Scholar
  59. 59.
    Geraghty PR, Kee ST, McFarlane G, et al. CT-guided transthoracic needle aspiration biopsy of pulmonary nodules: needle size and pneumothorax rate. Radiology. 2003;229:475–481.PubMedCrossRefGoogle Scholar
  60. 60.
    Richardson CM, Pointon KS, Manhire AR, Macfarlane JT. Percutaneous lung biopsies: a survey of UK practice based on 5444 biopsies. Br J Radiol. 2002;75:731–735.PubMedGoogle Scholar
  61. 61.
    Nyman J, Johansson K-A, Hultén U. Stereotactic hypofractionated radiotherapy for stage I nonsmall cell lung cancer — mature results for medically inoperable patients. Lung Cancer. 2006;51:97–103.PubMedCrossRefGoogle Scholar
  62. 62.
    The University of Texas MD Anderson Cancer Center. International randomized study to compare CyberKnife® stereotactic radiosurgery with surgical resection in stage I non-small cell lung cancer. Study Summary. http://utm-ext01a.mdacc.tmc.edu/dept/prot/clinicaltrialswp.nsf/Index/2007-0870. Accessed July 1, 2011.

Copyright information

© Springer Healthcare 2011

Authors and Affiliations

  • Oisin J. O’Connell
    • 1
  • Marcus P. Kennedy
    • 1
  • Michael T. Henry
    • 1
  1. 1.Department of Respiratory MedicineCork University HospitalWilton, CorkIreland

Personalised recommendations